Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Full-time Department: Other Contract Type: Permanent Company Description AFRY is a leading European engineering, design and consulting services company with a global presence. As a company, we are driving the transition to a more sustainable society.